Observational analysis evaluates eligibility for resmetirom treatment in predominantly F2/F3 fibrosis patients, indicating potential for targeted therapy.
Background: The THR-β agonist resmetirom is the first treatment approved for metabolic dysfunction-associated steatohepatitis (MASH) in the US so far. It can be prescribed given MASH and F2/F3-fibrosis ("at-risk MASH").
No takes yet. Share an insight, caveat, or question.
Messer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: